X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ASTRAZENECA PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ASTRAZENECA PHARMA ORCHID PHARMA LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x 0.1 176.6 0.1% View Chart
P/BV x 0.2 26.8 0.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ASTRAZENECA PHARMA
Mar-14
ORCHID PHARMA LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,285 15.1%   
Low Rs35634 5.5%   
Sales per share (Unadj.) Rs276.5189.6 145.8%  
Earnings per share (Unadj.) Rs-79.2-0.2 38,904.4%  
Cash flow per share (Unadj.) Rs-43.53.8 -1,130.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.968.6 78.6%  
Shares outstanding (eoy) m70.4525.00 281.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.45.1 8.2%   
Avg P/E ratio x-1.4-4,712.7 0.0%  
P/CF ratio (eoy) x-2.6249.6 -1.1%  
Price / Book Value ratio x2.114.0 15.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,06723,988 33.6%   
No. of employees `0002.81.6 179.6%   
Total wages/salary Rs m2,5271,605 157.5%   
Avg. sales/employee Rs Th6,956.13,040.2 228.8%   
Avg. wages/employee Rs Th902.51,029.2 87.7%   
Avg. net profit/employee Rs Th-1,993.0-3.3 61,041.9%   
INCOME DATA
Net Sales Rs m19,4774,740 410.9%  
Other income Rs m40792 442.1%   
Total revenues Rs m19,8844,832 411.5%   
Gross profit Rs m1,103-130 -849.5%  
Depreciation Rs m2,519101 2,489.3%   
Interest Rs m5,2270-   
Profit before tax Rs m-6,236-139 4,489.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511139 367.9%   
Tax Rs m-1255 -2,459.7%   
Profit after tax Rs m-5,580-5 109,632.6%  
Gross profit margin %5.7-2.7 -206.7%  
Effective tax rate %2.0-3.7 -54.8%   
Net profit margin %-28.7-0.1 26,679.0%  
BALANCE SHEET DATA
Current assets Rs m11,0142,726 404.0%   
Current liabilities Rs m32,0602,435 1,316.6%   
Net working cap to sales %-108.16.1 -1,757.6%  
Current ratio x0.31.1 30.7%  
Inventory Days Days9574 128.6%  
Debtors Days Days3441 82.3%  
Net fixed assets Rs m29,4401,035 2,843.6%   
Share capital Rs m70550 1,409.0%   
"Free" reserves Rs m2,043942 216.7%   
Net worth Rs m3,8001,716 221.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,5104,156 1,119.1%  
Interest coverage x-0.2NM-  
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.1 36.7%   
Return on assets %-0.8-0.1 620.6%  
Return on equity %-146.9-0.3 49,509.1%  
Return on capital %-3.70-  
Exports to sales %37.95.7 664.4%   
Imports to sales %22.66.5 350.1%   
Exports (fob) Rs m7,378270 2,730.4%   
Imports (cif) Rs m4,406306 1,438.5%   
Fx inflow Rs m7,513375 2,005.7%   
Fx outflow Rs m5,649470 1,201.5%   
Net fx Rs m1,865-96 -1,951.3%   
CASH FLOW
From Operations Rs m1,682-8 -20,761.7%  
From Investments Rs m-9,860-146 6,767.6%  
From Financial Activity Rs m6,644862 770.6%  
Net Cashflow Rs m-1,535709 -216.7%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 0.3 1,533.3%  
FIIs % 3.3 15.7 21.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 9.1 607.7%  
Shareholders   84,811 12,856 659.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS